녹농균 감염 치료 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pseudomonas aeruginosa infection treatment market size in 2026 is estimated at USD 2.3 billion, growing from 2025 value of USD 2.18 billion with 2031 projections showing USD 3.02 billion, growing at 5.58% CAGR over 2026-2031.

This report is Segmented by Treatment (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral, Inhalation / Nasal and Topical), Distribution Channel (Hospital Pharmacies, Retail Phamacies and Online Phamacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Pseudomonas Aeruginosa Infection Treatment Market Trends and Insights

Rising Prevalence of Hospital-Acquired Infections

Hospital environments create a near-ideal reservoir for Pseudomonas aeruginosa, especially where intensive care units rely on mechanical ventilation and invasive catheters. European surveillance indicates more than 3.5 million healthcare-associated infections yearly, leading to over 90,000 deaths, of which 71% involve antibiotic-resistant organisms. Ventilator-associated pneumonia remains a critical subset, with mortality climbing to 35.1% in extensively drug-resistant episodes.These statistics spur hospitals to favor dual-agent protocols able to break through biofilms and tackle adaptive resistance.

Growing R&D Investment in Antipseudomonal Drugs

Funding consortia such as CARB-X have channelled significant capital toward novel mechanisms, exemplified by support for Forge Therapeutics' metallo-enzyme inhibitors and Phico Therapeutics' engineered phage platform. The GAIN Act has granted 147 qualified infectious disease product designations, accelerating review cycles for breakthrough agents.Partnerships such as Eli Lilly-OpenAI illustrate how artificial intelligence now underpins lead-compound discovery pipelines.

Rapid Emergence of Multidrug Resistance

Genetic plasticity fuels swift adaptation, with Portuguese tertiary centers reporting 3.7% extensively drug-resistant prevalence and 35.1% mortality. OprD porin loss confers carbapenem resistance, yet complete multidrug resistance requires intertwined efflux and B-lactamase pathways that force clinicians toward dual agents.

Other drivers and restraints analyzed in the detailed report include:

1. Increasing Chronic Lung Disease Burden (CF, COPD)
2. Regulatory Incentives for Phage & Novel Antibiotic Platforms
3. High Cost of Next-Generation Antibiotics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Combination regimens commanded 54.95% of the Pseudomonas aeruginosa infection treatment market in 2025 and are advancing at a 9.58% CAGR through 2031. This dominance is anchored in robust Phase 3 evidence showing ceftolozane-tazobactam plus amikacin outperforming monotherapy for carbapenem-resistant infections. The Pseudomonas aeruginosa infection treatment market size for combination therapy is expected to reach USD 2.07 billion by 2031 on the back of synergistic mechanisms that block efflux, disable B-lactamases, and disrupt biofilm matrices. Even as monotherapies remain pivotal for fully susceptible isolates and select outpatient indications, next-generation hybrids such as aztreonam/avibactam or cefepime/enmetazobactam are redefining clinical thresholds for adequate coverage. Phage-antibiotic cocktails further expand the clinical toolkit, leveraging bacteriophages to perforate biofilms and ferry antibiotics into protected micro-colonies.

A deeper examination reveals how dual-agent protocols also mitigate supply-chain disruptions. Hospitals cushion against single-drug shortages by stocking versatile combinations spanning multiple mechanisms, thereby tempering the 42% higher shortage rate seen with antimicrobials. Meanwhile, stewardship committees favor combinations that deliver rapid bactericidal activity, shorten hospital stays, and cut downstream costs associated with prolonged ICU support. These clinical and economic advantages explain why the Pseudomonas aeruginosa infection treatment market continues to gravitate toward dual-agent strategies.

Complete Report Scope:

• By Treatment
  • Monotherapy
  • Combination Therapy
• By Route of Administration
  • Intravenous
  • Oral
  • Inhalation / Nasal
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online / Mail-Order Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America holds firm at a 34.02% revenue share thanks to well-funded hospitals, aggressive stewardship mandates, and early uptake of QIDP-designated drugs. The region's Veterans Health Administration surveillance shows shifting resistance profiles across 14 years, prompting continuous protocol updates and shifting formulary priorities. The United States accelerated approvals for EXBLIFEP and EMBLAVEO in less than a year, reinforcing a pragmatic regulatory environment that accelerates innovation. Canada's provincial health reforms emphasize rapid diagnostic reimbursement, while Mexico increasingly codifies stewardship into national accreditation programs, giving the Pseudomonas aeruginosa infection treatment market strong regional headroom.

Asia-Pacific is the fastest riser, clocking an 8.55% CAGR as health ministries expand universal coverage and molecular labs. Carbapenem resistance reaches a mean 31.3% across the region, necessitating robust investment in rapid diagnostics and phage research. Japan exemplifies best-practice alignment, with 78.8% adherence to febrile neutropenia guidelines that pivot toward B-lactamase inhibitor combinations. China's national surveillance network now integrates real-time genomic tracking, while India balances its role as the world's antibiotic supplier with quality-control initiatives to curb substandard exports.

Europe demonstrates stable but sizable opportunity. Coordinated ECDC surveillance links antimicrobial use to resistance, informing guideline updates that favor rapid switch-to-oral strategies and high-dose prolonged infusions. Regulatory alignment enabled the European Commission to green-light EMBLAVEO for pathogen-limited options, illustrating responsive policy to clinical evidence. Southern Europe's higher resistance burden drives combination therapy uptake, while Scandinavian countries leverage low antibiotic consumption to maintain comparatively lower resistance levels. Overall, the Pseudomonas aeruginosa infection treatment market remains primed for steady gains within western European strongholds and accelerated growth in central and eastern transition economies.

1. Abbvie
2. Teva Pharmaceutical Industries
3. Pfizer
4. Lupin
5. AstraZeneca
6. Merck
7. Bristol-Myers Squibb
8. Johnson & Johnson
9. Neopharma
10. CARB-X
11. Sanofi
12. Shionogi & Co.
13. GlaxoSmithKline
14. Novartis
15. Roche
16. Basilea Pharmaceutica
17. Insmed
18. Zambon S.p.A.
19. Cipla
20. Hikma Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence Of Hospital-Acquired Infections
  • 4.2.2 Growing R&D Investment In Antipseudomonal Drugs
  • 4.2.3 Increasing Chronic Lung Disease Burden (CF, COPD)
  • 4.2.4 Regulatory Incentives For Phage & Novel Antibiotic Platforms
  • 4.2.5 Adoption Of Inhaled Nano-Formulations Improving Adherence
  • 4.2.6 Expansion Of Rapid Molecular Diagnostics
• 4.3 Market Restraints
  • 4.3.1 Rapid Emergence Of Multidrug Resistance
  • 4.3.2 High Cost Of Next-Generation Antibiotics
  • 4.3.3 Cold-Chain Gaps For Liposomal Inhaled Products In LICs
  • 4.3.4 Tighter Antimicrobial-Stewardship Protocols In High-Income Health Systems
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Treatment
  • 5.1.1 Monotherapy
  • 5.1.2 Combination Therapy
• 5.2 By Route of Administration
  • 5.2.1 Intravenous
  • 5.2.2 Oral
  • 5.2.3 Inhalation / Nasal
  • 5.2.4 Topical
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online / Mail-Order Pharmacies
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 AbbVie (Allergan)
  • 6.3.2 Teva Pharmaceutical Industries
  • 6.3.3 Pfizer
  • 6.3.4 Lupin
  • 6.3.5 AstraZeneca
  • 6.3.6 Merck & Co.
  • 6.3.7 Bristol Myers Squibb
  • 6.3.8 Johnson & Johnson
  • 6.3.9 Neopharma
  • 6.3.10 CARB-X
  • 6.3.11 Sanofi
  • 6.3.12 Shionogi & Co.
  • 6.3.13 GSK
  • 6.3.14 Novartis
  • 6.3.15 F. Hoffmann-La Roche Ltd
  • 6.3.16 Basilea Pharmaceutica
  • 6.3.17 Insmed Incorporated
  • 6.3.18 Zambon S.p.A.
  • 6.3.19 Cipla
  • 6.3.20 Hikma Pharmaceuticals

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment